India Genetic Testing Market Overview,2030

The genetic testing market in India is evolving rapidly, driven by a combination of technological advancement, growing healthcare awareness, and an increasing focus on personalized and preventive medicine. As the country experiences a rise in lifestyle-related diseases, hereditary disorders, and cancers, genetic testing is becoming a vital tool in early diagnosis, risk assessment, and treatment planning. India’s large and genetically diverse population provides a vast resource for genomic studies, making it an attractive market for both domestic and global biotech companies. Government initiatives such as the Genome India Project have been instrumental in mapping the genetic diversity of the Indian population, which is expected to revolutionize the understanding of disease susceptibility and drug response among different ethnic groups. Additionally, the rapid growth of private diagnostic laboratories and startups like MedGenome, MapmyGenome, and Strand Life Sciences has made genetic testing more accessible and affordable to consumers. The increasing integration of genetic testing in oncology, prenatal screening, and carrier testing is also contributing to its demand, with healthcare professionals recognizing its potential in precision medicine. Educational awareness campaigns and the influence of digital health platforms have further helped bridge the knowledge gap, encouraging people to take a proactive approach toward health and wellness through genetic testing.

According to the research report, ""India Genetic Testing Market Overview, 2030,"" published by Bonafide Research, the India Genetic Testing market is expected to reach a market size of more than USD 17.36 Billion by 2030. Indian genetic testing market are expanding significantly due to the country’s growing investment in biotechnology, advancements in sequencing technology, and supportive policy frameworks. The Department of Biotechnology (DBT) and Indian Council of Medical Research (ICMR) are actively promoting genomic research and ethical testing standards, helping shape a responsible and innovation-driven ecosystem. One of the major trends driving growth is the rising interest in direct-to-consumer (DTC) genetic testing, which allows individuals to understand their genetic predispositions for fitness, nutrition, and ancestry. The affordability of next-generation sequencing (NGS) and the availability of skilled professionals have also encouraged local production and reduced dependency on imports. India’s strong IT and data analytics infrastructure is enabling the integration of artificial intelligence (AI) and machine learning into genetic data interpretation, improving accuracy and diagnostic efficiency. Moreover, increasing collaborations between hospitals, research centers, and global pharmaceutical firms are accelerating clinical applications of genomics in drug discovery and precision oncology. Ethical and privacy concerns are being addressed through the Personal Data Protection Bill, which aims to regulate the use and sharing of genetic information responsibly. A unique feature of India’s market is its focus on community genetics addressing inherited disorders prevalent in specific regions and communities through screening programs and genetic counseling. With its combination of scientific talent, digital innovation, and government support, India is positioning itself as a rising powerhouse in the global genetic testing landscape, offering vast opportunities for innovation, accessibility, and healthcare transformation in the years ahead.

The product segment includes test kits, reagents, consumables, sequencing platforms, analyzers, and bioinformatics software used for clinical diagnostics and research purposes. The rising burden of cancer, diabetes, cardiovascular diseases, and rare genetic disorders is fueling demand for advanced diagnostic tools and high-quality testing products. Indian biotechnology firms such as MapmyGenome, MedGenome, Strand Life Sciences, and Piramal Diagnostics are developing indigenous genetic testing kits and bioinformatics solutions tailored to the Indian genome diversity. These local innovations are complemented by imports of high-end sequencing instruments and reagents from global manufacturers like Illumina, Thermo Fisher Scientific, and Roche. The service segment, however, dominates the market due to the growing number of clinical laboratories, hospitals, and specialized diagnostic centers offering genetic testing. Urban centers like Mumbai, Delhi, Bengaluru, and Hyderabad are emerging as genomic hubs, with private and government hospitals incorporating genetic testing for disease risk assessment, reproductive health, and oncology. Direct-to-consumer (DTC) genetic testing services are also growing rapidly in India, especially among younger, tech-savvy populations seeking ancestry, lifestyle, and wellness-related insights. At the same time, clinical-grade genetic testing services supervised by physicians and certified genetic counsellors are expanding to meet rising medical needs. Government programs such as Ayushman Bharat Digital Mission and initiatives promoting “Make in India” for diagnostics are strengthening infrastructure and encouraging public-private partnerships. While products drive technological advancement, the services segment continues to lead due to rising test adoption rates, better affordability, and increased public health initiatives that promote genomic literacy and preventive diagnostics across India.

NGS is driving innovation across oncology, rare disease diagnostics, and population genomics due to its ability to sequence large volumes of DNA efficiently and cost-effectively. Research institutions such as the Indian Institute of Science (IISc), CSIR-Centre for Cellular and Molecular Biology (CCMB), and National Institute of Biomedical Genomics (NIBMG) are spearheading NGS-based projects, contributing to both research and clinical applications. The Polymerase Chain Reaction (PCR) remains a foundational technology, widely used in hospitals and diagnostic labs for single-gene testing, infectious disease detection, and reproductive health screening. Its affordability and reliability make it ideal for widespread use, particularly in tier II and III cities where advanced sequencing may not yet be accessible. Microarray-based testing plays a critical role in cytogenetics, pharmacogenomics, and gene expression studies, supporting research on inherited disorders and drug response variability among India’s genetically diverse population. In-situ Hybridization (ISH), especially FISH techniques, is gaining traction in oncology and pathology for detecting chromosomal abnormalities and tumor-specific biomarkers. Moreover, the integration of AI-powered bioinformatics, digital PCR, and CRISPR-based diagnostics is advancing test precision and interpretation speed. India’s participation in national genomic initiatives such as the Genome India Project aims to create a detailed genetic map of the Indian population, which will help identify disease predispositions and improve healthcare outcomes. Regulatory bodies like the Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT) are also setting quality and validation standards to ensure reliability and ethical compliance.

Oncology testing is the most dominant application, driven by the increasing incidence of cancer and the growing use of genetic profiling for precision oncology. NGS-based tumor panels are widely used to detect actionable mutations and guide targeted therapies in cancers such as breast, lung, ovarian, and colorectal. Major hospitals and diagnostic networks such as Tata Memorial Centre, Apollo Hospitals, and MedGenome Labs are leading efforts to integrate genomic data into cancer care and clinical trials. Reproductive health testing is another major growth area, encompassing prenatal screening, carrier testing, and preimplantation genetic diagnosis (PGD). With rising awareness of maternal and child health, non-invasive prenatal testing (NIPT) is becoming increasingly common in fertility clinics and obstetric practices across major cities. Genetic disease testing is gaining national attention as awareness of rare and inherited disorders increases. Conditions like thalassemia, sickle cell anemia, cystic fibrosis, and muscular dystrophy are being diagnosed earlier through molecular testing and newborn screening programs initiated by state governments. India’s demographic diversity also presents unique opportunities for large-scale genetic screening to identify population-specific mutations and hereditary risk factors. Beyond these, other clinical applications including pharmacogenomics, nutrigenomics, and preventive health are rapidly expanding. Pharmacogenomic testing is being integrated into clinical practice to help physicians personalize drug prescriptions and improve treatment efficacy while reducing side effects. Additionally, consumer-driven genetic health and wellness testing is gaining traction among individuals interested in fitness, diet, and longevity optimization. The government’s focus on digital health integration and genomic data storage is helping create a more connected healthcare ecosystem, where genetic information can be used for predictive and preventive care.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Genetic Testing Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Type
• Products (Consumables, Equipment)
• Services

By Technique
• Next-generation Sequencing (NGS)
• Polymerase Chain Reaction
• Microarrays
• In-situ Hybridization
• Others

By Application
• Oncology Testing
• Reproductive Health Testing
• Genetic Diseases (Rare & Common)
• Other Clinical (Pharmacogenomics, etc.) 
Show more